Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis.
Nelly FrossardAlexandra CoïcThibaut SaguetAlain CoïcFranck HimbertQuoc Tuan DoJean-Luc GalziCarey Meredith SuehsGerald GuillaumetPascal BonnetPhilippe BernardPublished in: International journal of cosmetic science (2024)
A cosmetic cream comprising the CCL17 neutraligand GPN279 improved the skin barrier and physiology criteria in patients with mild-to-moderate atopic dermatitis.